When itwas unveiled in 2012, people had great hopes that the gene editor CRISPR/Cas9could treat or even cure hundreds to thousands of genetic diseases. This year,researchers in the United States began testing the gene editor in people, acrucial first step in determining whether the technology can fulfill itsmedical promise.
These first clinical trials are testing CRISPR/Cas9s safety and efficacy against cancer, blood disorders and one form of inherited blindness in people who already have the disease (SN: 8/31/19, p. 6). Many more such trials are expected to begin soon. Unlike the editing of human embryos that stirred up controversy in 2018 (SN: 12/22/18 & 1/5/19, p. 20), the genetic changes introduced in these trials would not be inherited by future generations.
CRISPRs rise as a potential medical tool happened inremarkably short time, says Janelle Waack, an intellectual property attorney atthe law firm Bass, Berry & Sims in Washington, D.C. She has been trackingthe dramatic growth of CRISPR patent filings, including for health care,medical research, agriculture and chemical processing. People are investing inthe technology and think it has great commercial value, she says.
These first tests in people are bellwethers of CRISPRsfuture, Waack says. Patients will benefit only if companies continue to investin the technology, and that investment may depend on whether these earlyclinical trials succeed.
CRISPR/Cas9 is a bacterial defense system against virusesthat scientists have repurposed to make precise changes to DNA in the cells ofhumans and other animals. A guide RNA tows the DNA-cutting enzyme Cas9 tospecific genes, where it slices through the DNA. In three clinical trials nowunder way in the United States, and one just completed, those cuts aredisabling genes or snipping out problem bits of DNA.
Results reported from the completed trial, led by researchers at the University of Pennsylvania, suggest that a CRISPR treatment designed to boost the cancer-fighting power of immune cells called T cells is safe. The results are from three patients two with multiple myeloma and one with sarcoma whose T cells were removed and edited in the lab. CRISPR disabled three genes in the T cells. Researchers then outfitted the cells with a warhead a gene that directs the cells to tumor cells that have a specific protein on their surfaces. While immune cells engineered to fight cancer, called CAR-Tcells, have been used in patients for years, souping up T cells with the help of CRISPR is a new innovation.
The findings, presented December 7 at the American Society of Hematology meeting in Orlando, Fla., showed that CRISPR-edited T cells took hold and reproduced in the cancer patients. None of the three people had any side effects associated with the cells. Thats good news since other revved-up T cells have caused high fevers, low blood pressure, seizures and other side effects (SN: 7/7/18, p. 22). However, the experimental treatment didnt slow the growth of the peoples cancers. Now that weve demonstrated safety and feasibility, well be much more focused on the effectiveness of the therapy, says Edward Stadtmauer, a hematologist and oncologist who led the trial.
Headlines and summaries of the latest Science News articles, delivered to your inbox
Similar tests of CRISPR-edited T cells are under way inChina. And CRISPR Therapeutics, a Cambridge, Mass.based company, expects tobegin three trials next year in which edited T cells target blood and kidneycancers, says Samarth Kulkarni, the companys chief executive officer.
CRISPR Therapeutics has already started trials with VertexPharmaceuticals, based in Boston and London, to remove and edit cells frompeople with the blood disorders sickle cell disease or beta-thalassemia. Theedits turn on production of fetal hemoglobin, usually made only until shortlyafter birth. Early results from one woman with beta-thalassemia and anotherwoman with sickle cell disease suggest that the edited cells are safe and makeenough fetal hemoglobin to relieve disease symptoms. While these data areearly, they show that this could be a onetime curative therapy for patients,Kulkarni said November 19 during a news briefing describing the results.
In another trial, researchers are snipping a small piece ofDNA out of cells in the eyes of people with an inherited form of blindnesscalled Leber congenital amaurosis 10. That DNA contains a mutation that causesthe blindness. The trial, conducted by Editas Medicine, also based inCambridge, Mass., and the global pharmaceutical company Allergan, is the first and for now, only trial using CRISPR to edit DNA directly in cells in thehuman body.
With direct editing, getting CRISPR to exactly the rightplace is the first challenge, Kulkarni says. From there, its impossible toknow whether the gene editor has made unwanted off-target edits as well.External editing allows researchers to check if the correct edits have beenmade, but the approach isnt feasible for many diseases.
Whether and how soon CRISPR becomes an accepted therapy, and how the U.S. government regulates the technology, may all depend in part on these initial trials. Everybody is paying careful attention, Waack says.
See the original post here:
- Myriad Announces Partnership with OptraHEALTH to Deliver Gene a New AI Based Information Tool for Hereditary Cancer Patients - BioSpace - July 6th, 2020
- Children's National Medical Center and AWS partner for genome project targeting COVID-19 - SiliconANGLE - July 6th, 2020
- Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer - BioSpace - July 6th, 2020
- Movers & Shakers, July 3 | BioSpace - BioSpace - July 6th, 2020
- The Future of Medicine Is Bespoke - Fair Observer - July 6th, 2020
- July: Genome sequencing rare diseases | News and features - University of Bristol - July 6th, 2020
- Dropping Race-Based eGFR Adjustment Gains Traction in US - Medscape - July 6th, 2020
- A New Generation of Coronavirus Tests Is Coming. Here's What to Expect. - The New York Times - July 6th, 2020
- Fine-tuning brain activity reverses memory problems in mice with autism mutation - Spectrum - July 6th, 2020
- Male fruit flies' decline in fertility with age is not only driven by changes in sperm - Mirage News - July 6th, 2020
- In the Future, Lab Mice Will Live in Computer Chips, Not Cages - Medscape - July 6th, 2020
- For cancer treatment and more, genetic-based precision medicine holds a lot of promise - Connecticut Magazine - May 31st, 2020
- Drug factories: GMOs and gene editing are poised to transform medicine. Here's how. - Genetic Literacy Project - May 31st, 2020
- How to know your risk factors for hypertension and whether high blood pressure is genetic - Insider - INSIDER - May 31st, 2020
- Venture capital found its footing in biotech. Then came the virus. - BioPharma Dive - May 31st, 2020
- Israeli Lab: Drugs For Gaucher Disease May Work Against Coronavirus, Other Viral Infections | Health News - NoCamels - Israeli Innovation News - May 31st, 2020
- Rapid Growth on Genetic Testing Market with COVID-19 Impact Analysis, Top Key Companies like Abbott Laboratories Bio-Rad Laboratories Inc.,... - May 31st, 2020
- insideHPC Special Report: HPC and AI for the Era of Genomics - insideHPC - May 31st, 2020
- More insight into the cytokine storm caused by Covid-19 could lead to a treatment - Health24 - May 31st, 2020
- UCalgary researchers launch 360-degree study of children and COVID-19 - UCalgary News - May 31st, 2020
- 4000 Years of contact, conflict and cultural change had little genetic impact in Near East - University of Birmingham - May 31st, 2020
- Precision Medicine Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 - Cole of Duty - May 31st, 2020
- NOT REAL NEWS: A look at what didn't happen this week - wausaupilotandreview.com - May 31st, 2020
- Precision Medicine Informs Cost-Effective Heart Disease Treatments - HealthITAnalytics.com - May 19th, 2020
- Colonizing Mars may require humanity to tweak its DNA - Space.com - May 19th, 2020
- Complement genes add to sex-based vulnerability in lupus and schizophrenia - Newswise - May 19th, 2020
- 23andMe Is Trying to Crack the Genetic Code Behind the Coronavirus - Motley Fool - May 19th, 2020
- Global Molecular Diagnostics Industry 2019-2029: Genetic Disorders, Cardiovascular Disorders, Infections and Cancer - Yahoo Finance UK - May 19th, 2020
- Prominent Cancer Researcher to Join DRI and Renown Health - GlobeNewswire - May 19th, 2020
- Research Roundup: HIV vaccination, diabetes two-in-one injection, hybrid fish genetics - The Stanford Daily - May 19th, 2020
- Singapore researches discover specific gene linked to Asian Lung Cancer - BSA bureau - May 19th, 2020
- Grant will help scientists break new ground in gene editing - Newswise - May 19th, 2020
- Genomic Medicine Market 2020 | Know the Latest COVID19 Impact Analysis And Strategies of Key Players: Ingersoll Rand, Johnson Controls, Daikin, United... - May 19th, 2020
- Dyne Therapeutics Accelerates Programs in Facioscapulohumeral Muscular Dystrophy (FSHD) with Exclusive Licensing of Technologies to Target Genetic... - May 19th, 2020
- Coronavirus immunity passports could create a world of 'us and them'. But here's why they make sense - Genetic Literacy Project - May 19th, 2020
- New Stem Cell-Based Topical Solution Helps Bald People Regrow Hair - SciTechDaily - May 19th, 2020
- Scientists race to find a cure or vaccine for the coronavirus. Here are the top drugs in development - CNBC - May 19th, 2020
- WHITEHALL ANALYTICA THE AI SUPERSTATE: Part 2 Is COVID-19 Fast-Tracking a Eugenics-Inspired Genomics Programme in the NHS? - Byline Times - May 19th, 2020
- CRISPR And CRISPR-Associated (Cas) Genes Market Size, Share, Trends and Forecast 2026 by Major Players and Business Opportunities Caribou... - May 19th, 2020
- Researchers: Disease affecting kids could be in the genes - Newsday - May 19th, 2020
- From Competition To Sharing: How Her Childrens Rare Disease Led Sharon Terry To Revolutionize Medical Research - Forbes - May 9th, 2020
- Infection rates may have links to cancer - Medical News Today - May 9th, 2020
- Twin peeks: Stanford inherits twin registry, expanding research options - Stanford Medical Center Report - May 9th, 2020
- Management of Fertility and Hormonal Health in Women at Risk for Hereditary Gynecologic Cancers - Endocrinology Advisor - May 9th, 2020
- Individualized mosaics of microbial strains transfer from the maternal to the infant gut - Newswise - May 9th, 2020
- The Falsehoods of the 'Plandemic' Video - FactCheck.org - May 9th, 2020
- Its in your genes Whether Covid lands you in hospital or not depends on your body - ThePrint - May 9th, 2020
- FDA approves Tabrecta, first targeted therapy to treat metastatic NSCLC - The Cancer Letter - May 9th, 2020
- Research into the health of unborn babies receives government funding - UNSW Newsroom - May 9th, 2020
- Genetics and Weight: Is There an Obesity Gene? - LIVESTRONG.COM - May 9th, 2020
- New medical foundation invests in COVID-19 research funding - News - The University of Sydney - May 9th, 2020
- What Do Your Genetics Have to Do With Your Chances of Dying From Coronavirus? - Vanity Fair - May 3rd, 2020
- Scientists Find New Way to Inject Plants With Medicine, And It May Help Save Our Crops - ScienceAlert - May 3rd, 2020
- Sarepta Therapeutics Announces Research Agreement with US Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as... - May 3rd, 2020
- Evanston hospitals expand to antibody testing - The Daily Northwestern - May 3rd, 2020
- Profits and Pride at Stake, the Race for a Vaccine Intensifies - The New York Times - May 3rd, 2020
- Data On Thousands Of Twins Reveals How Genetics Influences Covid-19 Symptoms - IFLScience - May 3rd, 2020
- The pieces of the puzzle of covid-19s origin are coming to light - The Economist - May 3rd, 2020
- LIST: UW awards $2.2 million to groups, scientists fighting the coronavirus in Wisconsin - WMTV - May 3rd, 2020
- World Laughter Day 2020: Why we must remember that laughter is indeed the best medicine - Hindustan Times - May 3rd, 2020
- When COVID-19 Mutates, What Are the Risks? - MedicineNet - May 3rd, 2020
- Facts that China is trying to suppress about origin of COVID-19 - WION - May 3rd, 2020
- COVID-19: What's RNA research got to do with it? - University of Rochester - May 3rd, 2020
- Medical, tech investments pay off in Covid-19 war - The Straits Times - May 3rd, 2020
- Welcome to the kingdom of the sick - Salon - May 3rd, 2020
- Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection - CMAJ - May 3rd, 2020
- XBiotech Identifies Super Bloods for the Development of a True Human COVID-19 Therapy - GlobeNewswire - May 3rd, 2020
- On National DNA Day, scientists are trying to take the colonialism out of genetics - Massive Science - April 26th, 2020
- Turning On the 'Off Switch' in Cancer Cells - Michigan Medicine - April 26th, 2020
- Turkey's top scientific body invests TL 2.3 billion on 16 vaccine projects over 5 years | Daily Sabah - Daily Sabah - April 26th, 2020
- Covid-19 will pass. What about the racism it has illuminated? - STAT - April 26th, 2020
- Infection Rate May Indicate a Future Diagnosis of Cancer - Cancer Network - April 26th, 2020
- Misleading coronavirus information falsely attributed to Johns Hopkins - AFP Factcheck - April 26th, 2020
- He signed up for a coronavirus vaccine trial using a method that's never been used in humans. Here's why. - CNN - April 26th, 2020
- New study could lead to therapeutic interventions to treat cocaine addiction - Newswise - April 26th, 2020
- As Cuomo Issues New Executive Order, Weill Cornell Medicine Ramps Up COVID-19 Testing - Cornell University The Cornell Daily Sun - April 26th, 2020
- Another Step Towards Earlier Detection of Pancreatic Cancer - MedPage Today - April 26th, 2020
- UW president, biochemistry chair and mathematics professor named to American Academy of Arts and Sciences - UW News - April 26th, 2020
- Mustang Bio Receives Advanced Therapy Medicinal Product Classification from European Medicines Agency for MB-107 Lentiviral Gene Therapy for X-Linked... - April 26th, 2020
- Childhood Psychopathology Linked to Higher Levels of Genetic Vulnerability of Adult Depression - Clinical OMICs News - April 26th, 2020